• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Pro resolving inflammatory effects of the lipid mediators of omega 3 fatty acids and its implication in SARS COVID-19.解析ω-3 脂肪酸的脂类介质的抗炎作用及其在 SARS-CoV-2 中的意义。
Med Hypotheses. 2020 Dec;145:110340. doi: 10.1016/j.mehy.2020.110340. Epub 2020 Oct 8.
2
Possibility of averting cytokine storm in SARS-COV 2 patients using specialized pro-resolving lipid mediators.利用特异性促解决脂质介质来避免 SARS-COV-2 患者的细胞因子风暴。
Biochem Pharmacol. 2023 Mar;209:115437. doi: 10.1016/j.bcp.2023.115437. Epub 2023 Jan 30.
3
Specialized pro-resolving mediator network: an update on production and actions.特异性促解决介质网络：产生和作用的最新研究进展。
Essays Biochem. 2020 Sep 23;64(3):443-462. doi: 10.1042/EBC20200018.
4
Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation.短期补充n-3脂肪酸而非阿司匹林可增加血浆促炎症消退介质。
J Lipid Res. 2014 Nov;55(11):2401-7. doi: 10.1194/jlr.M045583. Epub 2014 Sep 3.
5
Specialized Pro-Resolving Lipid Mediators: Emerging Therapeutic Candidates for Multiple Sclerosis.特异性促解决脂质介质：多发性硬化症的新兴治疗候选药物。
Clin Rev Allergy Immunol. 2021 Apr;60(2):147-163. doi: 10.1007/s12016-020-08796-4.
6
The function of specialized pro-resolving endogenous lipid mediators, vitamins, and other micronutrients in the control of the inflammatory processes: Possible role in patients with SARS-CoV-2 related infection.专门的促解决内源性脂质介质、维生素和其他微量营养素在控制炎症过程中的功能：在 SARS-CoV-2 相关感染患者中的可能作用。
Prostaglandins Other Lipid Mediat. 2022 Apr;159:106619. doi: 10.1016/j.prostaglandins.2022.106619. Epub 2022 Jan 12.
7
Specialized pro-resolving mediators in respiratory diseases.呼吸系统疾病中的特异性促解决介质。
Curr Opin Clin Nutr Metab Care. 2022 Mar 1;25(2):67-74. doi: 10.1097/MCO.0000000000000805.
8
Disruption of pulmonary resolution mediators contribute to exacerbated silver nanoparticle-induced acute inflammation in a metabolic syndrome mouse model.破坏肺部修复介质会导致代谢综合征小鼠模型中银纳米颗粒引起的急性炎症加剧。
Toxicol Appl Pharmacol. 2021 Nov 15;431:115730. doi: 10.1016/j.taap.2021.115730. Epub 2021 Sep 30.
9
n-3 Fatty acid supplementation and proresolving mediators of inflammation.n-3脂肪酸补充与炎症的促消退介质
Curr Opin Lipidol. 2016 Feb;27(1):26-32. doi: 10.1097/MOL.0000000000000262.
10
Acute severe SARS COVID-19 patients produce pro-resolving lipids mediators and eicosanoids.急性重症 SARS-CoV-2 患者可产生促解决脂质介质和类二十烷酸。
Eur Rev Med Pharmacol Sci. 2021 Nov;25(21):6782-6796. doi: 10.26355/eurrev_202111_27123.

引用本文的文献

1
Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection.新冠病毒感染后的代谢改变和针对冠状病毒感染的潜在治疗靶点。
Signal Transduct Target Ther. 2023 Jun 7;8(1):237. doi: 10.1038/s41392-023-01510-8.
2
Association between blood N-3 fatty acid levels and the risk of coronavirus disease 2019 in the UK Biobank.英国生物库中血液 N-3 脂肪酸水平与 2019 年冠状病毒病风险的关联。
Am J Clin Nutr. 2023 Feb;117(2):357-363. doi: 10.1016/j.ajcnut.2022.11.011.
3
Specialized pro-resolving lipid mediators regulate inflammatory macrophages: A paradigm shift from antibiotics to immunotherapy for mitigating COVID-19 pandemic.特殊促消退脂质介质调节炎性巨噬细胞：从抗生素到免疫疗法以缓解新冠大流行的范式转变。
Front Mol Biosci. 2023 Feb 3;10:1104577. doi: 10.3389/fmolb.2023.1104577. eCollection 2023.
4
N-3 polyunsaturated fatty acids may affect the course of COVID-19.N-3 多不饱和脂肪酸可能会影响 COVID-19 的病程。
Front Immunol. 2022 Sep 27;13:957518. doi: 10.3389/fimmu.2022.957518. eCollection 2022.
5
Potential role of lipoxin in the management of COVID-19: a narrative review.脂氧素在 COVID-19 管理中的潜在作用：叙述性综述。
Inflammopharmacology. 2022 Dec;30(6):1993-2001. doi: 10.1007/s10787-022-01070-3. Epub 2022 Sep 16.
6
Effects of nutrients on immunomodulation in patients with severe COVID-19: Current knowledge.营养物质对重症新型冠状病毒肺炎患者免疫调节的影响：当前认知
World J Crit Care Med. 2022 Jul 9;11(4):201-218. doi: 10.5492/wjccm.v11.i4.201.
7
Nutrition as Personalized Medicine against SARS-CoV-2 Infections: Clinical and Oncological Options with a Specific Female Groups Overview.营养作为对抗 SARS-CoV-2 感染的个性化医学：特定女性群体的临床和肿瘤学选择概述。
Int J Mol Sci. 2022 Aug 15;23(16):9136. doi: 10.3390/ijms23169136.
8
Inverse Association between Omega-3 Index and Severity of COVID-19: A Case-Control Study.ω-3 指数与 COVID-19 严重程度呈负相关：一项病例对照研究。
Int J Environ Res Public Health. 2022 May 25;19(11):6445. doi: 10.3390/ijerph19116445.
9
The effect of polyunsaturated fatty acids on the severity and mortality of COVID patients: A systematic review.多不饱和脂肪酸对 COVID 患者严重程度和死亡率的影响：系统评价。
Life Sci. 2022 Jun 15;299:120489. doi: 10.1016/j.lfs.2022.120489. Epub 2022 Mar 28.
10
The role of antigen-presenting cells in the pathogenesis of COVID-19.抗原呈递细胞在新冠病毒疾病发病机制中的作用。
Pathol Res Pract. 2022 May;233:153848. doi: 10.1016/j.prp.2022.153848. Epub 2022 Mar 23.

解析ω-3 脂肪酸的脂类介质的抗炎作用及其在 SARS-CoV-2 中的意义。

Pro resolving inflammatory effects of the lipid mediators of omega 3 fatty acids and its implication in SARS COVID-19.

机构信息

Exeltis Healthcare, Adalperostr. 84, 85737 Ismaning, Germany.

Solutex SA, Avenida de la Transición Espanola 24, 28108 Alcobendas, Spain.

出版信息

Med Hypotheses. 2020 Dec;145:110340. doi: 10.1016/j.mehy.2020.110340. Epub 2020 Oct 8.

DOI:10.1016/j.mehy.2020.110340
PMID:33069094
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7543931/
Abstract

COVID-19 is a new disease caused by coronavirus SARS-CoV-2. It was first described in 2019, developed into an epidemic in January 2020 and has spread the global to the present COVID-19 pandemic. Specialized pro‑resolving mediators (SPMs) may play a new role in the management of this lung disease because SPM actively stimulate the resolution of infectious inflammation and are organ protective in animal disease models. Many tissues have been suitable targets for treating inflammation with SPMs or their active precursors 18-HEPE, 17-HDHA and the 14-HDHA, in order to elicit dynamic resolution of inflammation. Here we discuss the possible mode of action of these substances in the management of SARS Covid 19.

摘要

新型冠状病毒肺炎（Corona Virus Disease 2019，COVID-19）由冠状病毒 SARS-CoV-2 引起，于 2019 年首次被描述，2020 年 1 月发展为流行疫情，目前已蔓延至全球 COVID-19 大流行。特殊的促分解介质（Specialized pro-resolving mediators，SPM）可能在这种肺部疾病的治疗中发挥新作用，因为 SPM 可积极刺激传染性炎症的消退，并在动物疾病模型中具有器官保护作用。为了引发炎症的动态消退，许多组织已成为用 SPM 或其活性前体 18-HEPE、17-HDHA 和 14-HDHA 治疗炎症的合适靶点。在这里，我们讨论了这些物质在 SARS-CoV-2 管理中的可能作用模式。